*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
We wanted to give you a quick intraday update on our new alert, BioStem Technologies Inc. (NASDAQ: BSEM).
Following our alert this morning, BSEM opened at 3.65 and has so far rallied to a high of 4.00, +9% gains from open to high.
This could be just the start of a much bigger opportunity unfolding.
The 20 and 50 day moving average is 3.67 and 3.68. A breakout and close above this level could set into play the 200 day moving average of 4.52, +23% upside from today’s open.
Wall Street is starting to pay attention to BSEM - and for good reason.
In July, the company announced:
“BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies”
BSEM “announced that the United States Patent and Trademark Office (USPTO) has issued four U.S. design patents covering the Company's proprietary fenestrated human placental allograft technologies.”
“The newly issued patents strengthen BioStem's intellectual property portfolio and provide additional protection for innovative allograft designs in surgical and wound care applications.”
U.S. Patent No. D1131805: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
“The patent is directed to fenestrated human placental allograft designs intended to improve conformability, fluid transfer and handling characteristics during clinical use. The technology supports applications in surgical and wound care environments where enhanced drainage, flexibility and tissue integration may help optimize placement and healing outcomes.”
U.S. Patent No. D1130758: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
“The patent is directed to fenestrated human placental allograft designs that facilitate fluid management. The design supports use in surgical and wound care settings where effective drainage is important.”
U.S. Patent No. D1130759: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
“The patent is directed to fenestrated allograft designs that preserve the structural integrity of amniotic and chorion tissues while supporting moisture management in complex wound environments.”
U.S. Patent No. D1130760: FENESTRATED HUMAN PLACENTAL ALLOGRAFT
“The patent is directed to fenestrated allograft designs that enable controlled fluid passage to support wound drainage and overall wound management across a range of applications.”
Here are some of the company’s comments from this press release:
"These newly issued patents represent another important step in strengthening the intellectual property foundation supporting our placental-derived allograft technologies," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "Protecting the innovations behind our products helps support our long-term growth strategy while reinforcing our commitment to advancing regenerative medicine through differentiated technologies designed to improve patient care."
Furthermore:
“The four patents further expand BioStem's growing intellectual property portfolio, which includes more than 100 patents and patent applications worldwide. BioStem continues to invest in innovation across placental tissue processing, preservation technologies, and allograft designs as it develops next-generation products for wound care and surgical applications.”
“BioStem's proprietary processing technologies are designed to optimize preservation of the innate structural and biological characteristics of placental tissues, supporting their use in a variety of clinical applications, including surgical and wound care procedures.”
Last week, the company announced:
“BioStem Technologies Announces Nasdaq Uplisting”
"Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "We believe this uplisting will expand our access to capital, improve market visibility and liquidity for our shareholders, and reinforce our ability to attract exceptional talent as we continue to grow. We are deeply grateful to our partners, investors, and stakeholders for their continued support throughout this process."
In addition, today the company “will release its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and webcast at 4:30 PM ET”, according to its July 29 press release.
We are continuing to monitor BSEM for a sustainable breakout opportunity.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher expect to be compensated nine thousand dollars by bank wire transfer on 8/12/26 for the distribution of this advertisement about BSEM dated 8/12/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.